S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
Log in
NASDAQ:DYN

Dyne Therapeutics Stock Forecast, Price & News

$28.61
-0.44 (-1.51 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$27.93
Now: $28.61
$29.80
50-Day Range
$18.87
MA: $22.55
$29.30
52-Week Range
$15.60
Now: $28.61
$29.93
Volume157,931 shs
Average Volume172,383 shs
Market Capitalization$1.30 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapies. The company was founded in 2017 and is based in Waltham, Massachusetts.

MarketRank

Overall MarketRank

1.43 out of 5 stars

Analyst Opinion: 2.5Community Rank: 3.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DYN
CUSIPN/A
CIKN/A
Phone781 786 8230
Employees36

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$1.30 billion
Next Earnings Date2/4/2021 (Estimated)
OptionableNot Optionable
$28.61
-0.44 (-1.51 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DYN News and Ratings via Email

Sign-up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Dyne Therapeutics (NASDAQ:DYN) Frequently Asked Questions

How has Dyne Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Dyne Therapeutics' stock was trading at $12.81 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, DYN stock has increased by 123.3% and is now trading at $28.61.
View which stocks have been most impacted by COVID-19
.

Is Dyne Therapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dyne Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Dyne Therapeutics stock.
View analyst ratings for Dyne Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Dyne Therapeutics?

Wall Street analysts have given Dyne Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Dyne Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Dyne Therapeutics' next earnings date?

Dyne Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Dyne Therapeutics
.

How were Dyne Therapeutics' earnings last quarter?

Dyne Therapeutics, Inc. (NASDAQ:DYN) posted its quarterly earnings results on Thursday, November, 5th. The company reported ($2.01) EPS for the quarter, missing the consensus estimate of ($0.88) by $1.13.
View Dyne Therapeutics' earnings history
.

What price target have analysts set for DYN?

4 equities research analysts have issued 1-year price targets for Dyne Therapeutics' stock. Their forecasts range from $27.00 to $47.00. On average, they expect Dyne Therapeutics' share price to reach $34.25 in the next year. This suggests a possible upside of 19.7% from the stock's current price.
View analysts' price targets for Dyne Therapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of Dyne Therapeutics' key competitors?

Who are Dyne Therapeutics' key executives?

Dyne Therapeutics' management team includes the following people:
  • Mr. Joshua T. Brumm, Pres, CEO, Treasurer, Sec. & Director (Age 42, Pay $277.31k)
  • Dr. Romesh Subramanian Ph.D., Co-Founder & Chief Scientific Officer (Age 55, Pay $411.66k)
  • Dr. Jonathan McNeill M.D., VP of Bus. Devel.
  • Mr. Jason P. Rhodes M.B.A., Co-Founder & Independent Chairman (Age 50)
  • Mr. Gene Kim, VP of Fin. (Age 44)
  • Ms. Susanna Gatti High M.B.A., Chief Operating Officer (Age 52)
  • Mr. Richard Scalzo, VP of Accounting & Admin. (Age 34)
  • Ms. Amy Reilly, VP of Corp. Communications & Investor Relations (Age 47)
  • Dr. Oxana Beskrovnaya Ph.D., Sr. VP & Head of Research (Age 59)
  • Dr. Thomas-Christian Mix M.D., Sr. VP of Clinical Devel. (Age 53)

When did Dyne Therapeutics IPO?

(DYN) raised $175 million in an initial public offering on Thursday, September 17th 2020. The company issued 10,300,000 shares at $16.00-$18.00 per share. JPMorgan, Jefferies, Piper Sandler and Stifel served as the underwriters for the IPO.

What is Dyne Therapeutics' stock symbol?

Dyne Therapeutics trades on the NASDAQ under the ticker symbol "DYN."

When does the company's lock-up period expire?

Dyne Therapeutics' lock-up period expires on Tuesday, March 16th. Dyne Therapeutics had issued 12,251,578 shares in its initial public offering on September 17th. The total size of the offering was $232,779,982 based on an initial share price of $19.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.

How do I buy shares of Dyne Therapeutics?

Shares of DYN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Dyne Therapeutics' stock price today?

One share of DYN stock can currently be purchased for approximately $28.61.

How big of a company is Dyne Therapeutics?

Dyne Therapeutics has a market capitalization of $1.30 billion. Dyne Therapeutics employs 36 workers across the globe.

What is Dyne Therapeutics' official website?

The official website for Dyne Therapeutics is www.dyne-tx.com.

How can I contact Dyne Therapeutics?

The company can be reached via phone at 781 786 8230 or via email at [email protected]

This page was last updated on 1/15/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.